GALLIMUNE 303 ND+IB+ART Water-in oil emulsion for injection

Authorised

- Newcastle disease virus, strain Ulster 2C, Inactivated
- Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Turkey rhinotracheitis virus, strain VCO3, Inactivated

Product identification

Medicine name:
GALLIMUNE 303 ND+IB+ART Water-in oil emulsion for injection
GALLIMUNE 303 ND + IB+ ART

Active substance:
Newcastle disease virus, strain Ulster 2C, Inactivated
Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
Turkey rhinotracheitis virus, strain VCO3, Inactivated

Target species:
Chicken (for reproduction)

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Newcastle disease virus, strain Ulster 2C, Inactivated

50.00 50% Protective Dose / 0.30 millilitre(s)

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
18.00 log10 haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Turkey rhinotracheitis virus, strain VCO3, Inactivated
0.76 interference percentage unit(s) / 0.30 millilitre(s)

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Chicken (for reproduction)**
  - Egg. 0 day
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AA21

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Slovenia

Package description:
(ID4): 1 Box with 10 Bottle (PolyPropylene) with 300 millilitre(s) (3000 millilitre(s))
(ID3): 1 Box with 1 Bottle (PolyPropylene) with 300 millilitre(s) (300 millilitre(s))
(ID2): 1 Box with 10 Bottle (PolyPropylene) with 150 millilitre(s) (1500 millilitre(s))
(ID1): 1 Box with 1 Bottle (PolyPropylene) with 150 millilitre(s) (150 millilitre(s))

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Animal Health France

Marketing authorisation date:
7/04/2006

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Agency For Medicinal Products And Medical Devices Of The Republic Of Slovenia

Authorisation number:
MR/V/0149/001

Date of authorisation status change:
7/04/2006

Reference member state:
Germany

Procedure number:
DE/V/0228/001

Concerned member states:
Belgium Cyprus Denmark Finland France Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Portugal Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 15/02/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.
